Evolus/$EOLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolus
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Ticker
$EOLS
Sector
Primary listing
Employees
394
Headquarters
Website
Evolus Metrics
BasicAdvanced
$465M
-
-$0.97
1.12
-
Price and volume
Market cap
$465M
Beta
1.12
52-week high
$17.12
52-week low
$5.71
Average daily volume
1.8M
Financial strength
Current ratio
2.274
Quick ratio
1.717
Long term debt to equity
-779.943
Total debt to equity
-830.506
Interest coverage (TTM)
-1.95%
Profitability
EBITDA (TTM)
-33.65
Gross margin (TTM)
67.18%
Net profit margin (TTM)
-22.31%
Operating margin (TTM)
-14.73%
Effective tax rate (TTM)
-1.14%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
-11.06%
Return on equity (TTM)
-18,729.61%
Valuation
Price to revenue (TTM)
1.648
Price to book
-24.92
Price to tangible book (TTM)
-24.92
Price to free cash flow (TTM)
-9.107
Free cash flow yield (TTM)
-10.98%
Free cash flow per share (TTM)
-0.789
Growth
Revenue change (TTM)
17.15%
Earnings per share change (TTM)
7.82%
3-year revenue growth (CAGR)
28.04%
3-year earnings per share growth (CAGR)
-11.67%
What the Analysts think about Evolus
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Bulls say / Bears say
The FDA approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid gels in February 2025, marking the first major HA filler breakthrough in a decade and expanding Evolus’ total addressable market by 78% to ~$6 billion (Business Wire).
Global net revenue in Q1 2025 rose 15.5% year-over-year to $68.5 million, driven by Jeuveau® market share gains and strong customer engagement, setting the stage for multi-product growth (Business Wire).
Evolus refinanced its credit facility on May 5, 2025, securing a $250 million term loan that reduces borrowing costs by 350 basis points and adds $100 million of discretionary capacity, significantly bolstering liquidity and financial flexibility (SEC.gov).
GAAP revenue of $69.4 million in Q2 2025 grew just 4% year-over-year but missed consensus by 15.4%, driven by a sharp drop-off in U.S. customer orders in the final two weeks of the quarter (Nasdaq).
Management cut full-year 2025 net revenue guidance to $295 million–$305 million from the prior $345 million–$355 million range, a roughly 15% downward revision reflecting ongoing softness in the U.S. aesthetic market (Business Wire).
GAAP operating loss widened to $10.2 million in Q2 2025, up from $7.7 million in Q2 2024, highlighting increased operating costs tied to new product launches and cost-structure optimization (MarketChameleon)).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Evolus Financial Performance
Revenues and expenses
Evolus Earnings Performance
Company profitability
Evolus News
AllArticlesVideos
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 days ago
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
Business Wire7 days ago
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evolus stock?
Evolus (EOLS) has a market cap of $465M as of September 15, 2025.
What is the P/E ratio for Evolus stock?
The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of September 15, 2025.
Does Evolus stock pay dividends?
No, Evolus (EOLS) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Evolus dividend payment date?
Evolus (EOLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolus?
Evolus (EOLS) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.